WASHINGTON, DC -- The U.S. Department of Health and Human Services announced that Wright State University will receive a $400,000 grant for clinical research on neurological disorders. This grant was made possible in part by Congressman Mike Turner’s support of the Coronavirus Response and Relief Supplemental Appropriations Act (CRRSAA), which appropriated funding to the National Institute of Neurological Disorders and Stroke (NINDS) for the purposes of grant funding for universities. Specifically, NINDS allocated the grant to WSU so they could continue their research on the neurological disease ALS.
“This announcement of a $400,000 grant for clinical research on neurological disorders recognizes Wright State University’s achievements as an important leader in neuroscience research. I’m grateful that the Health and Human Services Department decided to issue this grant and to have supported the funding that made this grant possible,” said Turner. “This grant will allow Wright State University to continue their important contributions to medical research, particularly into the neurological disease ALS. I will continue to support the innovation and research by our great colleges and universities in the Dayton region.”
Wright State University Communications Director Seth Bauguess said of the award:
"Wright State University is excited to receive this federal grant, which will fund important research into the devastating neurological disease ALS,” said Bauguess. “The grant will also support the work of undergraduate and graduate student researchers, who represent the future of the battle against crippling diseases like ALS. We are grateful for the support of Congressman Mike Turner in this effort."
Wright State's externally sponsored grant and contract awards regularly approach $100 million. More than half of that funding is used to support basic and applied research projects, capitalizing on Wright State’s expertise in the areas of sensors, health care, human performance, cybersecurity, and cognitive and social sciences.